Stocks/GMAB/News

GMAB stock news today

Headlines, SEC filings, press releases, analyst ratings and earnings for GMAB from the last 90 days. Updated Nov 16, 2026.

Analyst: 11

Friday, November 13, 2026

AnalystMorgan Stanley

Morgan Stanley kept its Equal-Weight rating on Genmab (GMAB) and lowered its price target to $56 from $57.

Friday, October 30, 2026

AnalystMorgan Stanley

Morgan Stanley kept its Equal-Weight rating on Genmab (GMAB) with a price target of $57.

AnalystGuggenheim

Guggenheim kept its Buy rating on Genmab (GMAB) and raised its price target to $80 from $58.

Thursday, October 29, 2026

AnalystTruist Securities

Truist Securities kept its Buy rating on Genmab (GMAB) and raised its price target to $67 from $45.

AnalystHC Wainwright & Co.

HC Wainwright & Co. kept its Buy rating on Genmab (GMAB) and raised its price target to $70 from $50.

Monday, October 26, 2026

AnalystTD Cowen

TD Cowen kept its Buy rating on Genmab (GMAB) and raised its price target to $52 from $43.

Wednesday, October 7, 2026

AnalystTruist Securities

Truist Securities kept its Buy rating on Genmab (GMAB) with a price target of $45.

AnalystGuggenheim

Guggenheim kept its Buy rating on Genmab (GMAB) and raised its price target to $58 from $54.

AnalystHC Wainwright & Co.

HC Wainwright & Co. kept its Buy rating on Genmab (GMAB) and raised its price target to $50 from $40.

Monday, October 5, 2026

AnalystGuggenheim

Guggenheim kept its Buy rating on Genmab (GMAB) and raised its price target to $54 from $42.

Monday, September 14, 2026

AnalystHC Wainwright & Co.

HC Wainwright & Co. kept its Buy rating on Genmab (GMAB).

Frequently asked questions

What is the latest news on GMAB?

Nov 13, 2026: Morgan Stanley kept its Equal-Weight rating on Genmab (GMAB) and lowered its price target to $56 from $57. (Morgan Stanley) · Oct 30, 2026: Morgan Stanley kept its Equal-Weight rating on Genmab (GMAB) with a price target of $57. (Morgan Stanley) · Oct 30, 2026: Guggenheim kept its Buy rating on Genmab (GMAB) and raised its price target to $80 from $58. (Guggenheim)

What are analysts saying about GMAB?

Nov 13, 2026: Morgan Stanley kept its Equal-Weight rating on Genmab (GMAB) and lowered its price target to $56 from $57. · Oct 30, 2026: Morgan Stanley kept its Equal-Weight rating on Genmab (GMAB) with a price target of $57. · Oct 30, 2026: Guggenheim kept its Buy rating on Genmab (GMAB) and raised its price target to $80 from $58.

Get GMAB news as it happens

Every headline, SEC filing and analyst action for GMAB on your live chart, with important news marked and alerts when it matters.

Try SEPT Free

More GMAB Research

GMAB FundamentalsGMAB AnalysisGMAB SEC FilingsSEPT Academy
Share:XRedditFacebookLinkedIn
© SEPT Investing. Headlines link to their original sources. Not financial advice. Trading involves risk.